Latest Breaking News On - Clinical program updates - Page 1 : comparemela.com

BiomX Reports First Quarter 2024 Financial Results and Provides Business and Program Updates

Following merger with Adaptive Phage Therapeutics in March, combined company reports funding sufficient to support important data readouts for lead clinical programs in 2025 Company will host a.

Biomx Reports First Quarter 2024 Financial Results And Provides Business And Program Updates

Following merger with Adaptive Phage Therapeutics in March, combined company reports funding sufficient to support important data readouts for lead c

Prelude Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update

BiomX Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Annexon Reports Fourth Quarter and Year-End 2023 Financial Results and Key Anticipated Milestones

Pivotal Phase 3 Data for ANX005 in Guillain-Barré Syndrome Expected in Second Quarter 2024 Initiation of Pivotal Phase 3 ANX007 ARCHER II Trial in Geographic Atrophy Expected in mid-2024, a Global.